AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17708098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide for remission induction in patients with generalized disease or Churg-Strauss syndrome with risk factors
Number of subjects: 0
Study 17708098 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine for maintenance of remission
Number of subjects: 0
Study 15611795 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential MTX (200 mg m(‐2) i.v. on days 1 and 15) followed by FU (600 mg m(‐2) i.v. on days 2 and 16) and LV rescue (15 mg p.o. q 6 h x 6 doses)
Number of subjects: 1945
Study 15611795 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (370 mg m(‐2) i.v. bolus) preceded by leucovorin (100 mg m(‐2) i.v. bolus on days 1-5)
Number of subjects: 1945
Study 11587367 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytosine arabinoside
Number of subjects: 0
Study 11587367 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in anthracyclines
Number of subjects: 0
Study 11587367 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of hematopoietic growth factors
Number of subjects: 0
Study 11587367 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation in first remission
Number of subjects: 0
Study 11587367 — intervention group
Group type: EXPERIMENTAL
Intervention: Modulation of the multidrug resistance phenotype
Number of subjects: 0
Study 11587367 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative allogeneic stem cell transplantation
Number of subjects: 0
Study 11587367 — intervention group
Group type: EXPERIMENTAL
Intervention: Refinements in autologous stem cell transplantation
Number of subjects: 0
Study 11587367 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulations of neoangiogenesis in the bone marrow
Number of subjects: 0
Study 11587367 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporation of gemtuzumab zogamicin into treatment regimens
Number of subjects: 0
Study 9144906 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg b.i.d.
Number of subjects: 242
Study 9144906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 16358396 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese subjects with binge eating disorder (BED) in multiple-item meal
Number of subjects: 0
Study 16358396 — intervention group
Group type: COMPARATOR
Intervention: Obese subjects without binge eating disorder (BED) in multiple-item meal
Number of subjects: 0
Study 16358396 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-weight bulimic patients (BN) in multiple-item meal
Number of subjects: 0
Study 16358396 — intervention group
Group type: COMPARATOR
Intervention: Non-obese controls in multiple-item meal
Number of subjects: 0
Study 16358396 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese subjects with or without binge-eating disorder in single-item meal (ice cream)
Number of subjects: 0
Study 16358396 — intervention group
Group type: COMPARATOR
Intervention: Non-obese controls in single-item meal (ice cream)
Number of subjects: 0
Study 16358396 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with bulimia nervosa (BN) in single-item meal (ice cream)
Number of subjects: 0
Study 3537019 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing with modified Widman flap procedure
Number of subjects: 16
Study 3537019 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing alone (control)
Number of subjects: 16
Study 29363261 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-Prenylnaringenin (8-PN)
Number of subjects: 16
Study 29363261 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-Prenylnaringenin (6-PN)
Number of subjects: 16
Study 29363261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 27056401 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 40
Study 25544027 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced REP (provider coaching; N=40 sites) for 6 months followed by Standard REP for 6 months
Number of subjects: 158
Study 25544027 — intervention group
Group type: COMPARATOR
Intervention: Standard REP (N=49 sites) for 6 months followed by 6 months of Enhanced REP for sites still not responding
Number of subjects: 158
Study 23628502 — intervention group
Group type: COMPARATOR
Intervention: Combined aerobic and resistance training (CTG, n=16)
Number of subjects: 48
Study 23628502 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training (ATG, n=15)
Number of subjects: 48
Study 23628502 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=17)
Number of subjects: 48
Study 21915003 — intervention group
Group type: EXPERIMENTAL
Intervention: 27-gauge SC button
Number of subjects: 100
Study 21915003 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-gauge catheter
Number of subjects: 100
Study 21915003 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-gauge catheter
Number of subjects: 100
Study 21915003 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-chevron securement
Number of subjects: 100
Study 21915003 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent semipermeable membrane dressing (TSM)
Number of subjects: 100
Study 21915003 — intervention group
Group type: COMPARATOR
Intervention: Overall incidence of technical challenges (TCs)
Number of subjects: 100
Study 21915003 — intervention group
Group type: COMPARATOR
Intervention: Infusion-site reactions (pain, erythema, swelling)
Number of subjects: 100
Study 18326598 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D [25(OH)D] concentrations
Number of subjects: 637
Study 18326598 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun exposure
Number of subjects: 637
Study 18326598 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 637
Study 17163239 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide 1.25 mg/day and potassium chloride
Number of subjects: 312
Study 17163239 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide 2.5 mg/day and potassium chloride
Number of subjects: 312
Study 17163239 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/day
Number of subjects: 312
Study 17163239 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg/day
Number of subjects: 312
Study 14557093 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator exams (sim)
Number of subjects: 23
Study 14557093 — intervention group
Group type: COMPARATOR
Intervention: Oral objective-structured clinical examination (OSCE) sessions (oral)
Number of subjects: 23
Study 10746824 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide (11 mg/day)
Number of subjects: 18
Study 10746824 — intervention group
Group type: COMPARATOR
Intervention: Glyburide (10 mg/day)
Number of subjects: 18
Study 9106905 — intervention group
Group type: EXPERIMENTAL
Intervention: m-CPP (0.08 mg/kg)
Number of subjects: 12
Study 9106905 — intervention group
Group type: COMPARATOR
Intervention: ondansetron (0.15 mg/kg)
Number of subjects: 12
Study 9106905 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron pretreatment with m-CPP
Number of subjects: 12
Study 9106905 — intervention group
Group type: COMPARATOR
Intervention: m-CPP with ondansetron pretreatment
Number of subjects: 12
Study 1390574 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic bracket with chemical retention
Number of subjects: 51
Study 1390574 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic bracket with mechanical retention
Number of subjects: 51
Study 1390574 — intervention group
Group type: COMPARATOR
Intervention: Metal bracket with foil-mesh base
Number of subjects: 51
Study 6460474 — intervention group
Group type: EXPERIMENTAL
Intervention: Acne treatment
Number of subjects: 331
Study 6460474 — intervention group
Group type: EXPERIMENTAL
Intervention: Acne grading scales and papule counts
Number of subjects: 331
Study 6460474 — intervention group
Group type: EXPERIMENTAL
Intervention: Comedo grading scale and comedo count
Number of subjects: 331
Study 6460474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study 31984445 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg D-cycloserine
Number of subjects: 50
Study 31984445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30633081 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbow position at 90 degrees
Number of subjects: 2
Study 30633081 — intervention group
Group type: COMPARATOR
Intervention: Elbow position at 20 degrees
Number of subjects: 2
Study 30633081 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller fragment group (0.6 cm osteotomy)
Number of subjects: 2
Study 28926288 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient palliative care integrated with transplant care
Number of subjects: 160
Study 28926288 — intervention group
Group type: COMPARATOR
Intervention: Transplant care alone
Number of subjects: 160
Study 25666504 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (50,000 IU/week for 6 months)
Number of subjects: 40
Study 25666504 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 40
Study 25388499 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare worker training
Number of subjects: 715
Study 21911655 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 IU of insulin
Number of subjects: 104
Study 21911655 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 IU of insulin
Number of subjects: 104
Study 21911655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 19444555 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol hydrochloride (0.125 mg x kg(‐1) x min(‐1) for 1 min, followed by 0.04 mg x kg(‐1) x min(‐1) infusion)
Number of subjects: 30
Study 19444555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19444555 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol hydrochloride
Number of subjects: 30
Study 17578462 — intervention group
Group type: EXPERIMENTAL
Intervention: NaCl 0.9%, 750 ml/m(2) body surface area (BSA)
Number of subjects: 50
Study 17578462 — intervention group
Group type: EXPERIMENTAL
Intervention: hydroxyethylic starch 10%, 250 ml/m(2) BSA and NaCl 0.9%, 400 ml/m(2) BSA
Number of subjects: 50
Study 17578462 — intervention group
Group type: EXPERIMENTAL
Intervention: dextran 10%, 250 ml/m(2) BSA and NaCl 0.9%, 300 ml/m(2) BSA
Number of subjects: 50
Study 17578462 — intervention group
Group type: EXPERIMENTAL
Intervention: hypertonic sodium chloride 7.2%/hyperoncotic hydroxyethylic starch 10%, 150 ml/m(2) BSA
Number of subjects: 50
Study 17578462 — intervention group
Group type: EXPERIMENTAL
Intervention: hypertonic sodium chloride 7.2%/hyperoncotic dextran 10%, 150 ml/m(2) BSA
Number of subjects: 50
Study 16484121 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐endoscopic clinical evaluation (symptom questionnaire, H. pylori serology, hemoglobin determination)
Number of subjects: 341
Study 12584485 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral and social skill (BSS) class for children with ADHD (8-week duration)
Number of subjects: 100
Study 12584485 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral and social skill (BSS) class for parents of children with ADHD
Number of subjects: 100
Study 12584485 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 100
Study 10224570 — intervention group
Group type: EXPERIMENTAL
Intervention: Silzone coating of St. Jude Medical Masters Series mechanical heart valves
Number of subjects: 4400
Study 10224570 — intervention group
Group type: COMPARATOR
Intervention: Conventional cuff of St. Jude Medical Masters Series mechanical heart valves
Number of subjects: 4400
Study 9086315 — intervention group
Group type: EXPERIMENTAL
Intervention: NaCl (0.2 g/kg/day)
Number of subjects: 32
Study 9086315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 2007961 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mmol/L alanine in WHO oral rehydration solution (ORS)
Number of subjects: 20
Study 2007961 — intervention group
Group type: COMPARATOR
Intervention: Standard WHO oral rehydration solution (ORS)
Number of subjects: 20
Study 6808838 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 3 percent ophthalmic ointment
Number of subjects: 59
Study 6808838 — intervention group
Group type: COMPARATOR
Intervention: Trifluorothymidine 2 percent ointment
Number of subjects: 59
Study 30333269 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate 5 mg
Number of subjects: 126
Study 30333269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 28040502 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PAD) with toluidine blue (0.1mg/mL) and LED lamp (635nm, 200mW/cm2) for 60s
Number of subjects: 20
Study 28040502 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide therapy (Ca(OH)2) for two weeks
Number of subjects: 20
Study 28040502 — intervention group
Group type: COMPARATOR
Intervention: Comparison between PAD and calcium hydroxide therapy
Number of subjects: 20
Study 26335189 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic medication (IFC group: Influcid®) for 7 days plus standard treatment (paracetamol, ambroxol, and/or oxymetazoline)
Number of subjects: 523
Study 26335189 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (ST group: paracetamol, ambroxol, and/or oxymetazoline)
Number of subjects: 523
Study 26335189 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic medication (IFC group: Influcid®)
Number of subjects: 523
Study 26335189 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (ST group)
Number of subjects: 523
Study 23937688 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid beverage deficient in dopamine precursors (phenylalanine and tyrosine)
Number of subjects: 0
Study 23937688 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 0
Study 21624895 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD patients without appropriate therapy
Number of subjects: 322
Study 21624895 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD patients with unused ICD
Number of subjects: 322
Study 18972875 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of 40 mg pantoprazole
Number of subjects: 74
Study 18972875 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of 40 mg pantoprazole
Number of subjects: 74
Study 15756211 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ppm inhaled nitric oxide (iNO)
Number of subjects: 860
Study 15756211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 860
Study 12504835 — intervention group
Group type: COMPARATOR
Intervention: B vitamins (folate, 10 mg; vitamin B-12, 200 microg; vitamin B-6, 20 mg/day)
Number of subjects: 27
Study 12504835 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (24 g/day)
Number of subjects: 27
Study 10373114 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation of pain
Number of subjects: 0
Study 10373114 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipation of pain
Number of subjects: 0
Study 8902440 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraamniotic administration of ethacridine lactate (82 patients)
Number of subjects: 340
Study 8902440 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical prostaglandin (PG) E2 gel (100 patients)
Number of subjects: 340
Study 8902440 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of concentrated oxytocin (36 patients)
Number of subjects: 340
Study 8902440 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (49 patients)
Number of subjects: 340
Study 8902440 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon insertion (73 patients)
Number of subjects: 340
Study 1879977 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil-SR 240 mg twice daily
Number of subjects: 20
Study 1879977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6368946 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential amino acid/keto acid mixture
Number of subjects: 0
Study 6368946 — intervention group
Group type: EXPERIMENTAL
Intervention: KMVA (keto‐isoleucine)
Number of subjects: 0
Study 6368946 — intervention group
Group type: EXPERIMENTAL
Intervention: KIVA (keto‐valine)
Number of subjects: 0
Study 6368946 — intervention group
Group type: EXPERIMENTAL
Intervention: KICA (keto‐leucine)
Number of subjects: 0
Study 31924275 — intervention group
Group type: EXPERIMENTAL
Intervention: SES-sensitive implementation strategy (blended care format with GP nurse guidance)
Number of subjects: 228
Study 31924275 — intervention group
Group type: COMPARATOR
Intervention: Regular implementation strategy
Number of subjects: 228
Study 31924275 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring and evaluating psychological complaints (depression, sleep, stress, worry, anxiety) and well-being
Number of subjects: 228
Study 30980680 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbapenem administration before or during chemotherapy
Number of subjects: 0
Study 30980680 — intervention group
Group type: COMPARATOR
Intervention: No carbapenem administration
Number of subjects: 0
Study 30980680 — intervention group
Group type: EXPERIMENTAL
Intervention: Abundance of Blautia in fecal microbiota
Number of subjects: 0
Study 28446297 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous mecobalamin (HDIME)
Number of subjects: 65
Study 28446297 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib-based chemotherapy (Control)
Number of subjects: 65
Study 25502222 — intervention group
Group type: EXPERIMENTAL
Intervention: Better Futures model (Summer Institute, individual peer coaching, mentoring workshops)
Number of subjects: 67
Study 25502222 — intervention group
Group type: EXPERIMENTAL
Intervention: Better Futures model
Number of subjects: 67
Study 25502222 — intervention group
Group type: COMPARATOR
Intervention: Typical services (control group)
Number of subjects: 67
Study 24345428 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting dihydrocodeine tablets (DHC-Continus)
Number of subjects: 60
Study 24345428 — intervention group
Group type: COMPARATOR
Intervention: Short-acting dihydrocodeine tablets
Number of subjects: 60
Study 24345428 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 22943608 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy group (surgical treatment + adjuvant radiotherapy)
Number of subjects: 62
Study 22943608 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgical treatment only)
Number of subjects: 62
Study 19954047 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous levofloxacin 500 mg once a day
Number of subjects: 4888
Study 17295714 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompression/stabilization operation in the cervical spine: the Smith/Robinson operation
Number of subjects: 32
Study 15029333 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective testing group (no preoperative testing unless new or worsening medical problem)
Number of subjects: 1025
Study 15029333 — intervention group
Group type: COMPARATOR
Intervention: Routine testing group (12-lead electrocardiogram, complete blood count, serum glucose level)
Number of subjects: 1025
Study 11298222 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective report style with schema consistent information
Number of subjects: 48
Study 11298222 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective report style with schema inconsistent information
Number of subjects: 48
Study 11298222 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective report style with schema consistent information
Number of subjects: 48
Study 11298222 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective report style with schema inconsistent information
Number of subjects: 48
Study 11298222 — intervention group
Group type: COMPARATOR
Intervention: Any report style
Number of subjects: 48
Study 9207281 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate (400 mg/day during 14 days every 3 months)
Number of subjects: 32
Study 9207281 — intervention group
Group type: COMPARATOR
Intervention: Fluoride (50 mg/day, enteric-coated tablets)
Number of subjects: 32
Study 8434331 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity, dynamic back extension and abdominal exercises with occurrence of low back pain being the limiting factor
Number of subjects: 96
Study 8434331 — intervention group
Group type: COMPARATOR
Intervention: Traditional program of mild, generally mobility‐improving exercises within pain limits
Number of subjects: 96
Study 3121288 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensure (hourly)
Number of subjects: 8
Study 3121288 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensure (4-hourly)
Number of subjects: 8
Study 3121288 — intervention group
Group type: COMPARATOR
Intervention: PHT without Ensure (A)
Number of subjects: 8
Study 3121288 — intervention group
Group type: EXPERIMENTAL
Intervention: PHT with Ensure (hourly) (B)
Number of subjects: 8
Study 3121288 — intervention group
Group type: EXPERIMENTAL
Intervention: PHT with Ensure (4-hourly) (C)
Number of subjects: 8
Study 29582543 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-operative caries treatment programme based on the Nexø method (NOCTP)
Number of subjects: 106
Study 29582543 — intervention group
Group type: EXPERIMENTAL
Intervention: Care as usual plus 2 extra professional fluoride applications (IPFA)
Number of subjects: 106
Study 29582543 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CONTROL)
Number of subjects: 106
Study 27304677 — intervention group
Group type: EXPERIMENTAL
Intervention: Adventurous Dreaming Highflying Dragon
Number of subjects: 73
Study 27304677 — intervention group
Group type: COMPARATOR
Intervention: Comparable full-body-driven game without ADHD-focused training components
Number of subjects: 73
Study 25413071 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase after 3 days of indwelling catheter
Number of subjects: 38
Study 25413071 — intervention group
Group type: COMPARATOR
Intervention: Control group (urokinase after onset of catheter dysfunction)
Number of subjects: 38
Study 23724615 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical calcipotriol and betamethasone dipropionate (combined regimen) for 4 weeks
Number of subjects: 50
Study 23724615 — intervention group
Group type: COMPARATOR
Intervention: Topical betamethasone valerate (monotherapy) for 4 weeks
Number of subjects: 50